Home › Funds › Context Capital Management, LLC › ARWR
Context Capital Management, LLC position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
Context Capital Management, LLC reported holding 18,400,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$22.0M, representing 0.64% of its reported portfolio and ranking #41 among its reported holdings. Context Capital Management, LLC has disclosed ARWR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Context Capital Management, LLC's ARWR position evolved
Context Capital Management, LLC first disclosed a stake in ARWR in Q1 2026 at 14,900,000 shares (US$15.5M). The position peaked in Q2 2026 at 18,400,000 shares, worth US$22.0M. Across 2 filings, Context Capital Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 18,400,000 shares valued at US$22.0M — an increase of 3,500,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 14.90M | $15.45M | New |
| Q2 2026 | 18.40M | $22.03M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 53 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 1.72M sh · $139.83M · Q2 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
More on Context Capital Management, LLC
FAQ
How long has Context Capital Management, LLC held ARWR?
Context Capital Management, LLC has disclosed ARWR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Context Capital Management, LLC's current position in ARWR?
As of Q2 2026, Context Capital Management, LLC holds 18.40M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $22.03M, representing 0.64% of its reported portfolio and ranking #41.
Has Context Capital Management, LLC been buying or selling ARWR?
In the latest 13F filing (Q2 2026), Context Capital Management, LLC increased its position in ARWR. The position peaked in Q2 2026 at 18.40M shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.